Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 67 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pervasive Developmental Disorder NOS Clear all
Not listed No phase listed Observational Accepts healthy volunteers

EEG Studies of Sensory Processing in Autistic Children

NCT00319722
View directory record Official record
Conditions
Autism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Months to 8 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Behavior Therapy for Irritability in Autism

NCT04654260
View directory record Official record
Conditions
Autism Spectrum Disorder, Irritability, Disruptive Behavior, Anger, Aggression, Asperger Syndrome, Pervasive Developmental Disorder
Interventions
Behavioral Therapy for Irritability in Autism, Psychoeducation and Supportive Therapy (PST)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
12 Years to 19 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Withdrawn Phase 2 Interventional

Mercury Chelation to Treat Autism

NCT00376194
View directory record Official record
Conditions
Autism, Asperger's Disorder, Child Development Disorders, Pervasive
Interventions
DMSA
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
4 Years to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Shared Decision Making to Improve Care and Outcomes for Children With Autism

NCT01921244
View directory record Official record
Conditions
Autistic Disorder, Pervasive Developmental Disorder, Child Development Disorders, Pervasive, Asperger Syndrome, Autism Spectrum Disorder, Autism
Interventions
Decision Aid
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 15 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 10, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)

NCT00579267
View directory record Official record
Conditions
Major Depression, Mania, Anxiety Disorders, Psychotic Disorder, Alcohol Dependence, Drug Dependence, Eating Disorders, Suicidality, Dysthymia, ADHD, Tourettes Disorder, Conduct Disorder, Oppositional Defiant Disorder, Pervasive Developmental Disorder
Interventions
MINI-KID
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 17 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2009 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

NCT01731119
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS, Autistic Disorder, Asperger Syndrome, Child Development Disorders, Pervasive, Bipolar I Disorder, Bipolar II Disorder, Mood Disorder NOS, Severe Major Depression With Psychotic Features, Single Episode Major Depression Without Psychotic Symptoms, Severe Mood Disorder With Psychotic Features
Interventions
Latuda©
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Years to 19 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety

NCT01919970
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Pervasive Developmental Disorder Not Otherwise Specified, Generalized Anxiety Disorder, Social Phobia, Separation Anxiety Disorder, Obsessive-compulsive Disorder, Specific Phobia
Interventions
Cognitive Behavioral Therapy, Treatment as usual
Other
Lead sponsor
University of South Florida
Other
Eligibility
6 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

NCT00251303
View directory record Official record
Conditions
Obsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder, Developmental Disorder
Interventions
Riluzole, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

D-Cycloserine and Social Skills Training in Autism Spectrum Disorders

NCT01086475
View directory record Official record
Conditions
Autistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder NOS
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 11 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)

NCT00166595
View directory record Official record
Conditions
Child Development Disorders, Pervasive
Interventions
Risperidone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
4 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
4
States / cities
Detroit, Michigan • Durham, North Carolina • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 10, 2026, 5:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Neurodevelopmental and Behavioral Phenotyping Screening Protocol

NCT00271622
View directory record Official record
Conditions
Neurologic Disorders, Autism, Neurodegenerative Disease, Neurobehavioral Manifestation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
6 Weeks and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Sep 10, 2026, 5:11 AM EDT
Completed No phase listed Observational

Advanced Grandparental Age as a Risk Factor for Autism

NCT00464477
View directory record Official record
Conditions
Autistic Disorder, Pervasive Developmental Disorder, Asperger Syndrome, Childhood Disintegrative Disorder, Rett Syndrome
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Aripiprazole in Children With Autism: A Pilot Study

NCT00208533
View directory record Official record
Conditions
Autism
Interventions
Aripiprazole
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

A Controlled Study of Olanzapine in Children With Autism

NCT00057408
View directory record Official record
Conditions
Autistic Disorder
Interventions
olanzapine (Zyprexa), Placebo
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
3 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 10, 2026, 5:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Characteristics Associated With Symptom Remission in Autism

NCT00938054
View directory record Official record
Conditions
Autism Spectrum Disorders, Autism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Not applicable Interventional

Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder

NCT01631851
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder (ASD, Asperger's Disorder, Pervasive Developmental Disorder (PDD-NOS)
Interventions
Cognitive-Behavioral Therapy (CBT) for Irritability
Behavioral
Lead sponsor
Yale University
Other
Eligibility
9 Years to 16 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 10, 2026, 5:11 AM EDT
Terminated Phase 3 Interventional

Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders

NCT01706523
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
STX209 (arbaclofen)
Drug
Lead sponsor
Seaside Therapeutics, Inc.
Industry
Eligibility
5 Years to 21 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645
View directory record Official record
Conditions
Autistic Disorder
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
5 Years to 17 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)

NCT00147394
View directory record Official record
Conditions
Child Development Disorders, Pervasive
Interventions
Risperidone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 16 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
5
States / cities
Detroit, Michigan • Durham, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2012 · Synced Sep 10, 2026, 5:11 AM EDT
Completed No phase listed Observational

Predictors of Caregiver Adaptation to Pervasive Developmental Disorders

NCT00496210
View directory record Official record
Conditions
Autism, Asperger's Syndrome, Rett's Disorder
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 4 Interventional Results available

Atomoxetine, Placebo and Parent Management Training in Autism

NCT00844753
View directory record Official record
Conditions
Autism, Pervasive Development Disorder, Asperger's Disorder, Attention Deficit Hyperactivity Disorder
Interventions
atomoxetine, Placebo, Parent Management Training
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
5 Years to 14 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
3
States / cities
Rochester, New York • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 10, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Sep 10, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders

NCT01302964
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Placebo, Mirtazapine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 10, 2026, 5:11 AM EDT